Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Heart Failure × Pyruvic Acid × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 1 Metabolic Syndrome 1 Heart Failure 1 Cardiovascular Diseases 1

Interventions

Control Groups 2 Atorvastatin 2 pertuzumab 1 nicotinamide-beta-riboside 1 empagliflozin 1 dapagliflozin 1 candesartan 1 Trastuzumab 1 Sodium Chloride 1 Simendan 1 Pyruvic Acid 1 Population Groups 1 Ogivri 1 Metoprolol 1 Hydroxymethylglutaryl-CoA Reductase Inhibitors 1 Eplerenone 1 Carvedilol 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06645691 2024-12-06

POLARIC-13

National Heart Centre Singapore

Phase 2 Recruiting

Cardiovascular Diseases, Heart Failure, Metabolic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡